Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Omeprazole and visual disorders: seeing alternatives.

M Lindquist1, M Pettersson, I R Edwards

  • 1The WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden.

Pharmacoepidemiology and Drug Safety
|January 1, 1996
PubMed
Summary

Visual disorders linked to omeprazole are rare, with a maximum reporting rate of 0.94 per million treatment days. Solicited reporting and newer drug status may explain apparent increases, not necessarily direct causation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of landscape on the distribution of inflammatory bowel disease in England and Wales.

BMC public health·2026
Same author

Poor Association Between Clinical Characteristics and Seropositivity in Children With Suspected Long COVID-A Single-Centre Study.

Acta paediatrica (Oslo, Norway : 1992)·2025
Same author

Whole-genome sequencing in prenatally detected congenital malformations: prospective cohort study in clinical setting.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same author

Identification of the Language Network from Resting-State fMRI in Patients with Brain Tumors: How Accurate Are Experts?

AJNR. American journal of neuroradiology·2023
Same author

Electronic field effect detection of SARS-CoV-2 N-protein before the onset of symptoms.

Biosensors & bioelectronics·2022
Same author

30-Day postoperative COVID-19 outcomes in 398 patients from regional hospitals utilising a designated COVID-19 minimal surgical site pathway.

Annals of the Royal College of Surgeons of England·2021

Area of Science:

  • Pharmacovigilance
  • Ophthalmology
  • Gastroenterology

Background:

  • Proton pump inhibitors like omeprazole are widely used.
  • Spontaneous reports of visual disorders with omeprazole, ranitidine, and cimetidine are rare.
  • Concerns have been raised regarding potential visual side effects of omeprazole.

Purpose of the Study:

  • To evaluate the incidence and potential causes of visual disorders associated with omeprazole.
  • To compare reporting rates of visual disturbances with omeprazole versus older proton pump inhibitors.
  • To explore possible pathophysiological mechanisms and confounding factors.

Main Methods:

  • Analysis of spontaneous adverse event reports in the WHO database.
  • Calculation of reporting rates per million treatment days for omeprazole and comparators.

Related Experiment Videos

  • Review of potential etiological factors, including vasculitis and reporting artifacts.

    • Main Results:

    • The maximum reporting rate for severe visual impairment with intravenous omeprazole was 0.94 reports per million treatment days in Germany.
    • The global reporting rate for all severe visual disorders with all administration routes was 0.008 reports per million treatment days.
    • Increased reporting in Germany coincided with the initial signal, suggesting a possible reporting artifact or increased surveillance.

    Conclusions:

    • Reported visual disturbances with omeprazole are rare and may be influenced by reporting artifacts and the drug's newer market status.
    • Vasculitis is an unlikely cause due to low reporting rates.
    • Further research, including community prevalence data and case-control studies, is needed to fully interpret these findings.